Steroid-sparing management of the salmeterol/fluticasone 50/100 microg b.i.d. [twice daily] combination compared to fluticasone 200 microg b.i.d. in children and adolescents with moderate asthma

Trial Profile

Steroid-sparing management of the salmeterol/fluticasone 50/100 microg b.i.d. [twice daily] combination compared to fluticasone 200 microg b.i.d. in children and adolescents with moderate asthma

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms VIAPAED
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 04 Oct 2008 This study was presented during the proceedings of the 18th Annual Congress of the European Respiratory Society.
    • 03 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top